Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Metronidazole
- Indications Bacterial vaginosis
- Focus Therapeutic Use
- Acronyms VARIANT
- Sponsors Alfa Wassermann SpA
- 07 Oct 2016 Status changed from recruiting to discontinued.
- 17 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Mar 2015 New trial record